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costs were assigned using standard costing methods (con-
verted to 2001 US$). Due to the nearly threefold between-
continent cost difference, data were analyzed separately.
Multivariate methods were used to adjust both cost and
effectiveness for baseline variables. Probabilities of treat-
ment beneﬁts were estimated using bootstrap methods.
RESULTS: The adjusted incremental total cost of treat-
ment was $932 and $484 lower for linezolid; the adjusted
incremental effectiveness was 5.8% and 6.4% higher with
linezolid when missing effectiveness was scored as fail-
ures, or 12.3% and 4.3% higher when missing effective-
ness was imputed, for the European and South American
patients, respectively; only the 12.3% increment reached
statistical signiﬁcance. The probability for the linezolid
group having both lower cost and superior effectiveness
was 65.3% and 86.9% when missing effectiveness was
scored as failures, or 75.2% and 80.7% when missing
effectiveness was imputed, for the European and South
American patients, respectively. CONCLUSIONS: The
results suggest that linezolid is likely to represent good
value for money compared to teicoplanin for the treat-
ment of serious gram-positive infections.
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OBJECTIVES: To prevent bacterial endocarditis (BE), 
the American Heart Association recommends antibiotics
prior to urinary catheterization (UC) in the presence of
known urinary tract infection (UTI). In young children
who undergo evaluation for fever, the presence of UTI is
unknown prior to UC. It is the objective of this study to
determine the cost-effectiveness of BE prophylaxis prior
to UC in febrile children aged 0–24 months with moder-
ate-risk cardiac lesions who present to the emergency
department. METHODS: Taking a societal perspective,
we determined the cost-effectiveness of BE prophylaxis 
in terms of 1) quality-adjusted life years (QALYs); and 
2) bacterial endocarditis incidence. Probabilities were
derived from the medical literature. Costs were derived
from national sources in US dollars for the reference year
2000, using a discount rate of 3%. Sensitivity analysis
was conducted by varying the individual costs and prob-
abilities. RESULTS: When antibiotic-associated deaths
are excluded, BE prophylaxis is more effective and more
costly than no prophylaxis. Prophylaxis prevents seven
cases of BE per 1 million children treated, with an incre-
mental effectiveness of 0.00005 QALYs. The incremental
cost-effectiveness ratio of amoxicillin is $10 million per
QALY gained and $72 million per case prevented. For
vancomycin, it is $13 million per QALY gained and $95
million per case prevented. When antibiotic-associated
deaths are included, the no prophylaxis strategy is more
effective and less costly than the prophylaxis strategy. The
results are otherwise robust to sensitivity analysis. CON-
CLUSIONS: In the emergency department, BE prophy-
laxis prior to UC in febrile children aged 0–24 months
with moderate-risk cardiac lesions is not cost-effective.
The results of this analysis do not support the use of BE
prophylaxis in these children.
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Paediatric meningitis is a major, life threatening disease
resulting in severe, lifetime sequelae. OBJECTIVE: To
estimate the lifetime cost to the New Zealand Govern-
ment of severe disability ensuing from paediatric pneu-
mococcal meningitis. METHODS: “Severe disability”
was deﬁned as ‘disability sufﬁcient to preclude enrolment
at a mainstream UK school.’ The epidemiology of paedi-
atric disability was obtained from a recent UK study of
survivors of pneumococcal meningitis, and validated
using Auckland data. Long-term costs were estimated
from age-speciﬁc cross-sectional data obtained from the
Ministries of Education, Health and Social Development
and 30 provider agencies. Representative healthcare costs
were obtained for the following services: home/carer
support packages; audiology, hearing devices and
cochlear implants for severe or profound bilateral sen-
sorineural hearing loss; assessment and rehabilitation ser-
vices for cerebral palsy and epilepsy; orthotics services for
cerebral palsy; residential facilities; specialised equip-
ment; housing modiﬁcations; GP consultations; pharma-
ceuticals; hospital costs for epilepsy and corrective
surgery for physical disabilities. Other costs comprised
disability allowances plus income and vocational support.
The cost from birth to age 64 years was obtained by mul-
tiplication of 3 matrices in 5-year age bands: weighted
mean annual costs across all categories of expenditure;
survival (from life tables) and an age-speciﬁc discounting
factor (at 5% discount rate). RESULTS: The Government
cost to age 64 of severe disability resulting from pneu-
mococcal meningitis contracted in the ﬁrst year of life is
estimated at $NZ0.88M ($US0.44M) discounted to
present value at 5% per annum ($NZ2.8M undis-
counted). This cost is sensitive to the distribution of dis-
ability by type and severity. The main costs are: individual
home and carer support (28%); education (23%); resi-
dential care (18%); income support (13%); environmen-
tal support (10%); and bilateral severe or profound
hearing loss (7%). CONCLUSIONS: Lifetime costs to 
the Government associated with severe disability result-
ing from paediatric pneumococcal meningitis are 
substantial.
